The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 202-211

  Parr, Christian ^a   Watkins, Gareth ^a   Mansel, Robert E ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR PROTEIN; MATRIPTASE 1; PROTEIN HAI 1; PROTEIN HAI 2; RNA; SCATTER FACTOR; SCATTER FACTOR ACTIVATOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL DIFFERENTIATION; DISEASE PROGRESSION; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOGLOBULIN G; LYMPH NODES; LYMPHATIC METASTASIS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-MET; RABBITS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; TRYPSIN INHIBITOR, KUNITZ SOYBEAN;

EID: 1642535487     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0553-3     Document Type: Article

References (52)

1. Grant, D. S., Kleinman, H. K., and Goldberg, I. D. Scatter factor induces blood-vessel formation in vivo. Proc. Natl. Acad. Sci. USA, 90: 1937-1941, 1993.
2. Sugawara, J., Fukaya, T., and Murakami, T. Hepatocyte growth factor stimulates proliferation, migration, and lumen formation of human endometrial epithelial cells in vitro. Biol. Reproduct., 57: 936-942, 1997.
3. Jiang, W. G., Hiscox, S., Matsumoto, K., and Nakamura, T. Hepatocyte growth factor/scatter factor/scatter factor, the molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol., 29: 209-248, 1999.
4. Tuck, A. B., Park, M., Sterns, E. E., Boag, A., and Elliott, B. E. Coexpression of hepatocyte growth factor and receptor (met) in human breast carcinoma. Am. J. Pathol., 148: 225-232, 1996.
5. Taniguchi, T., Toi, M., and Tominaga, T. Increase in the circulating level of hepatocyte growth factor in breast cancer patients with distant metastases. Oncol. Rep., 1: 1199-1201, 1994.
6. Woodbury, R. L., Varnum, S. M., and Zangar, R. C. Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. J. Proteome Res., 1: 233-237, 2002.
7. Elliot, B. E., Hung, W. L., Boag, A. H., and Tuck, A. B. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition in breast cancer. Can. J. Physiol. Pharmacol., 80: 91-102, 2002.
8. Taniguchi, T., Toi, M., Inada, K., Imazawa, T., Yamamoto, Y., and Tominaga, T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin. Cancer Res., 1: 1031-1034, 1995.
9. Narita, T., Toi, M., Sekiguchi, K., Iwanari, H., Matsuura, N., Kimura, N., Mitsuoka, C., and Kannagi, R. Hepatocyte growth factor in the sera of patients with gastrointestinal and breast cancer. Gan To Kagaku Ryoho, 24: 2159-2162, 1997.
10. Fukuura, T., Miki, C., Inoue, T., Matsumoto, K., and Suzuki, H. Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br. J. Cancer, 78: 454-459, 1998.
11. Yamashita, J., Ogawa, M., Yamashita, S., Nomura, K., Kuramoto, M., Saishoji, T., and Shin, S. Immunoreactive hepatocyte growth-factor is a strong and independent predictor of recurrence and survival in human breast-cancer. Cancer Res., 54: 1630-1633, 1994.
12. Soman, N. R., Correa, P., Ruiz, B. A., and Wogan, G. The TPR-met oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc. Natl. Acad. Sci. USA, 88: 4892-4896, 1991.
13. Di Renzo, M. F., Narsiman, R. P., Olivero, M., Bretti, S., Giolano, S., Medico, E., Gaglia, P., Zara, P., and Comoglio, P. M. Expression of the MET/HGF receptor in normal and neoplastic human tissues. Oncogene, 6: 1997-2003, 1991.
14. Di Renzo, M. F., Olivero, M., Ferro, S., Prat, M., Bongarzone, I., Pilotti, S., Belfiore, A., Costantino, A., Vigneri, R., Pierotti, M. A., and Comoglio, P. M. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene, 7: 2549-2553, 1992.
15. Di Renzo, M. F., Olivero, M., and Katsaros, D. Overexpression of the met/HGF receptor in ovarian cancer. Int. J. Cancer, 58: 658-662, 1994.
16. Di Renzo, M. F., Poulsom, R., and Olivero, M. Expression of the met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res., 55: 1129-1138, 1995.
17. Watanabe, M., Fukutome, K., Kato, H., Murata, M., Kawamura, J., Shiraishi, T., and Yatani, R. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett., 141: 173-177, 1999.
18. Ruco, L. P., Stoppacciaro, A., Ballarini, F., Prat, M., and Scarpino, S. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenic role in tumorigenesis. J. Pathol., 194: 4-8, 2001.
19. Beviglia, L., Matsumoto, K., Lin, C. S., Ziober, B. L., and Kramer, R. H. Expression of the c-met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int. J. Cancer, 74: 301-309, 1997.
20. Camp, R. L., Rimm, E. B., and Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer (Phila.), 86: 2259-2265, 1999.
21. Ghoussoub, R. A., Dillon, D. A., D'Aquila, T., Rimm, E. B., Fearson, E. R., and Rimm, D. L. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer (Phila.), 82: 1513-1518, 1998.
22. Miyazawa, K., Shimomura, T., Kitamura, A., Kondo, J., Morimoto, Y., and Kitamura, N. Molecular-cloning and sequence-analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth-factor - structural similarity of the protease precursor to blood-coagulation factor-xii. J. Biol. Chem., 268: 10024-10028, 1993.
23. Miyazawa, K., Shimomura, T., Daiji, N., and Kitamura, N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J. Biol. Chem., 269: 8966-8970, 1994.
24. Lee, S., Dickson, R. B., and Lin, C. Y. Activation of Hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem., 275: 36720-36725, 2000.
25. Shimomura, T., Denda, K., Kitamura, A., Kawaguchi, T., Kito, M., Kondo, J., Kagaya, S., Qin, L., Takata, H., Miyazawa, K., and Kitamura, N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J. Biol. Chem., 272: 6370-6376, 1997.
26. Kawaguchi, T., Qin, L., Shimomura, T., Kondo, J., Matsumoto, K., Denda, K., and Kitamura, N. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J. Biol. Chem., 272: 27558-27564, 1997.
27. Oberst, M., Anders, A., Xie, B., Singh, B., Ossandon, M., Johnson, M., Dickson, R. B., and Lin, C. Y. Matriptase and HAI1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol., 158: 1301-1311, 2001.
28. Nakamura, T., Matsumoto, K., Kiritoshi, A., Tano, Y., and Nakamura, T. Induction of hepatocyte growth factor in fibroblasts by tumorderived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res., 57: 3305-3313, 1997.
29. Parr, C., and Jiang, W. G. Expression of hepatocyte growth factor/ scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol., 19: 857-863, 2001.
30. Jiang, W. G., Douglas-Jones, A., and Mansel, R. E. Level of expression of PPAR-γ and its co-activator (PPAR-GCA) in human breast cancer. Int. J. Cancer, 106: 752-757, 2003.
31. Parr, C., and Jiang, W. G. Quantitative analysis of lymphangiogenesis in human colon cancer. Int. J. Oncol., 23: 533-539, 2003.
32. Martin, K. J., and Pardee, A. B. Identifying expressed genes. Proc. Natl. Acad. Sci. USA, 97: 3789-3791, 2000.
33. Toi, M., Taniguchi, T., Ueno, T., Asano, M., Funata, N., Sekiguchi, K., Iwanari, H., and Tominaga, T. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin. Cancer Res., 4: 659-664, 1998.
34. Yao, Y. Jin, L. Fuchs, A. Joseph, A. Hastings, H. W. Goldberg, I. D., and Rosen, E. M. Scatter factor protein levels in human breast cancers - clinicopathological and biological correlations. Am. J. Pathol., 149: 1707-1717, 1996.
35. Tsarfaty, I., Alvord, W. G., Resau, J. H., Altstock, R. T., Lidereau, R., Bieche, I., Bertrand, F., Horev, J., Klabansky, R. L., and Vande Woude, G. F. Alteration of MET protooncogene product expression and prognosis in breast carcinomas. Am. J. Epidemiol., 5: 397-408, 1999.
36. Kang, J. Y., Dolled-Filhart, M., Ocal, I. T., Singh, B., Lin, C. Y., Dickson, R. B., Rimm, D. L., and Camp, R. L. Tissue microarray analysis of hepatocyte growth factor/met pathway components reveals a role for met, matriptase and hepatocyte growth factor activator inhibitor I in the progress of node-negative breast cancer. Cancer Res., 63: 1101-1105, 2003.
37. Nagata, K., Hirono, S., Ido, A., Kataoka, H., Moriuchi, A., Shimomura, T., Hori, T., Hayashi, K., Koono, M., Kitamura, N., and Tsubouchi, H. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 289: 205-211, 2001.
38. Kataoka, H., Hamasuna, R., Itoh, H., Kitamura, N., and Koono, M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res., 60: 6148-6159, 2000a.
39. Itoh, H., Kataoka, H., Tomita, M., Hamasuna, R., Yukifumi, N., Kitamura, N., and Koono, M. Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa. Am. J. Physiol. Gastrointest. Liver Physiol., 278: 635-643, 2000.
40. Kataoka, H., Itoh, H., and Koono, M. Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration. Pathol. Int., 52: 89-102, 2002.
41. Muller-Pillasch, F., Wallrapp, C., Bartels, K., Varga, G., Friess, H., Buchler, M., Adler, G., and Gress, T. M. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain over expressed in pancreatic cancer. Biochim. Biophys. Acta, 1395: 88-95, 1998.
42. Kataoka, H., Itoh, H., Uchino, H., Hamasuna, R., Kitamura, N., Nabeshima, K., and Koono, M. Conserved expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin in human colorectal carcinomas. Cancer Lett., 148: 127-134, 2000b.
43. Kobayashi, H., Suzuki, M., Kanayama, N., Takashi, N., Takigawa, M., and Terao, T. Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependant cascade. Eur. J. Biochem., 269: 3945-3957, 2002.
44. Grondahl-Hansen, J., Christensen, I. J., and Rosenquist, C. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53: 2513-2521, 1993.
45. Pederson, N., Schmitt, M. R., and Ronne, E. Prognostic significance of urokinase, urokinase receptor and type-1 plasminogen activator inhibtor in squamous- and large-cell lung-cancer tissues. Cancer Res., 54: 120-123, 1994.
46. Van Der Burg, M. E. L., Henzen-Longmans, S. C., and Berns, E. M. J. J. Expression of urokinase-type plasminogen activator (uPA) and its inhibtor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer, 69: 475-479, 1996.
47. Allgayer, H., Babic, R., and Grutzner, K. U. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin. Exp. Metastasis, 16: 62-73, 1998.
48. Heiss, M. M., Babic, R., and Allgayer, H. Tumor associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol., 8: 2084-2093, 1995.
49. Berger, D. H. Plasmin/plasminogen system in colorectal cancer. World J. Surg., 26: 767-771, 2002.
50. Denda, K., Shimomura, T., Kawaguchi, T., Miyazawa, K., and Kitamura, N. Functional characterisation of kunitz domains in hepatocyte growth factor activator inhibtor type-1. J. Biol. Chem., 277: 14053-14059, 2002.
51. Kataoka, H., Shimomura, T., Kawaguchi, T., Hamasuna, R., Itoh, H., Kitamura, N., Miyazawa, K., and Koono, M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenviroenvironment. J. Biol. Chem., 275: 40453-40462, 2000c.
52. Shimomura, T., Denda, K., Kawaguchi, T., Matsumoto, K., Miyazawa, K., and Kitamura, N. Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form. J. Biochem., 126: 821-828, 1999.